|
 |
AdalimumabThis page contains recent news articles, when available, and an overview of Adalimumab but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Adalimumab (when available) Used in the treatment of rheumatoid arthritis. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of the disease. Adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting the joint destruction. For treatment of rheumatoid arthritis Mechanism Of Action: Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. News Articles on Adalimumab UK's NICE says Bristol Myers' Orencia not recommended for ... - 23 Apr 2008 The drugs are adalimumab, marketed in the UK as Humira by Abbott Laboratories (nyse: ABT - news - people ); etanercept, marketed in the UK as Enbrel by Forbes, UCB's Cimzia gets approval in the USA for Crohn's disease - 23 Apr 2008 Now Cimzia can start trying to take market share of Abbott Laboratories rival Crohn's disease drug Humira (adalimumab), which was approved by the FDA over a Pharma Times (subscription), Abbott Announces HUMIRA® (adalimumab) Approved In Japan For The ... - Apr 21, 2008 Abbott announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare for HUMIRA® (adalimumab) for the treatment of Medical News Today (press release), Tumor necrosis factor alpha drugs in rheumatoid arthritis ... - Apr 17, 2008 To analyse available evidence on the efficacy and safety of anti-TNF drugs (infliximab, etanercept and adalimumab) for treating rheumatoid arthritis (RA). 7thSpace Interactive (press release), Some Biologics Are More Cost-Effective than Others in RA - Apr 16, 2008 Explain to interested patients that this study found that etanercept and adalimumab are more cost-effective in treating rheumatoid arthritis in Medicare MedPage Today, Study details cost-effectiveness of rheumatoid arthritis ... - Apr 14, 2008 Our analysis suggests that the use of etanercept or adalimumab in place of infliximab as a first-line biologic agent is likely to be considered cost Genetic Engineering News (press release), Latest rheumatoid arthritis drugs compared - Apr 16, 2008 This group of drugs, known as anti-TNFα drugs (which include infliximab, etanercept and adalimumab), are now commonly used to treat RA. EurekAlert (press release), Abbott earnings rise 35% as Humira sales soar - Apr 17, 2008 The stellar performance came from Humira (adalimumab), which is approved for six indications in the USA, ranging from rheumatoid arthritis, Crohn’s disease Pharma Times (subscription), UNIchip protein biochips from Protagen identify significant off ... - Mar 31, 2008 Both Etanercept and Adalimumab showed off-target activity, with Etanercept binding to 10 proteins with affinities greater than 20% of its binding affinity PharmaLive.com (press release), Humira now indicated for psoriasis in adults: Abbott Laboratories ... - Apr 8, 2008 The Food and Drug Administration has approved Abbott Laboratories' Humira (adalimumab) for the treatment of moderate to severe chronic plaque psoriasis in Therapeutics Daily (subscription) (press release), As Use of Biologicals Rises, So Too Will Cutaneous Reactions to ... - Mar 24, 2008 Nearly 1 billion patients have been treated with infliximab, nearly 500000 with etanercept, and about 200000 with adalimumab. DG News Eisai, Abbott Win Japanese Approval for Humira Drug (Update1) - Apr 16, 2008 Humira, also known as adalimumab, is designed to block a human protein called tumor necrosis factor, which causes inflammation. Eisai shares were unchanged Bloomberg Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the ... - Apr 16, 2008 Labour and Welfare for HUMIRA(R) (adalimumab) for the treatment of rheumatoid arthritis in patients with inadequate response to conventional therapy. CNNMoney.com (press release) Injectables to drive growth in US drug delivery market to 2012 - Apr 9, 2008 The report suggests that the success of drugs such as Roche's Herceptin (trastuzumab) and Abbott's Humira (adalimumab) in cancer and autoimmune diseases In-PharmaTechnologist.com, EISAI Announces that HUMIRA(R) received approval for the treatment ... - Apr 16, 2008 Ltd. (Headquarters in Tokyo, President and CEO: Haruo Naito) announced that HUMIRA(R) (adalimumab), Abbott's fully-human monoclonal anti-TNF- antibody Japan Corporate News (press release), FDA Approves Adalimumab for the Treatment of Juvenile Idiopathic ... - Feb 22, 2008 The US Food and Drug Administration has approved adalimumab (Humira) for the treatment of moderately to severely active JIA in persons aged 4 years and DG News Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for ... - Feb 22, 2008 By Abbott Abbott (NYSE: ABT) announced today it has received US Food and Drug Administration (FDA) approval to market HUMIRA(R) (adalimumab) as a treatment SunHerald.com, Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for ... - Feb 22, 2008 22 -- Abbott announced today it has received US Food and Drug Administration (FDA) approval to market HUMIRA(R) (adalimumab) as a treatment to reduce signs Earthtimes, Relief for arthritis sufferers - Mar 6, 2008 As of March 14, rheumatologists can help patients get coverage of adalimumab, etanercept and infliximab for eligible patients through the Pharmacare Special Vancouver Sun, Humira Approved for Children's Arthritis - Feb 22, 2008 22 (HealthDay News) -- The US Food and Drug Administration has approved Humira (adalimumab) to treat moderate-to-severe juvenile idiopathic arthritis (JIA) Forbes, Humira Approved for New Indication - Feb 26, 2008 Fewer children treated with Humira (adalimumab) in the study experienced disease flare compared with those on placebo, according to the company. FDA news (subscription), Humira Approved for Treatment of Juvenile Rheumatoid Arthritis - Feb 26, 2008 Abbott recently announced that they received approval from the US Food and Drug Administration to market Humira (adalimumab) as treatment to reduce the MedHeadlines, Market Report -- In Play (ABT) - Feb 22, 2008 ...to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis MSN Money Drug decision was years in the making - Mar 7, 2008 Effective March 14, 2008 rheumatologists can apply using specialized forms for coverage of adalimumab (Humira), etanercept (Enbrel) and infliximab BCLocalNews, Effect of tumor necrosis factor a inhibitors on heart failure risk ... - Feb 27, 2008 Anti-TNF drugs such as infliximab, etanercept, and adalimumab have been shown to not only diminish signs and symptoms of the disease, but also prevent joint EurekAlert (press release), Belgium's UCB releases impressive Cimzia data in Crohn's - Mar 5, 2008 If approved, Cimzia would compete with Abbott Laboratories’ Humira (adalimumab), which was approved by the FDA in January. UCB has also submitted a BLA for Pharma Times (subscription), Call for shake-up of biologic regulations for psoriasis - Mar 4, 2008 Raptiva, Genentec, Xoma, Merck/Serono), etanercept (Enbrel, Amgen, Wyeth), infliximab (Remicade, Centocor) and adalimumab (Humira, Abbott). Pharma Times (subscription), Priced out of the UK market - Feb 22, 2008 In August, 2007, Humira (adalimumab) from Abbott Laboratories of Abbott Park, Illinois, got the nod in the treatment of psoriatic arthritis at a cost of Nature.com (subscription), Unmet Needs Provide Challenges and Opportunities for Rheumatoid ... - Feb 26, 2008 Puricase (pegloticase; Savient); Remicade (infliximab; Centocor/Schering-Plough/Essex), Enbrel (etanercept; Wyeth/Amgen); Humira (adalimumab; Abbott), PR Newswire (press release), New Biologic Option for Crohn's Disease Offers a Welcome Option ... - Feb 25, 2008 Another biologic tumor necrosis factor (TNF) inhibitor, Abbott Laboratories' Humira (adalimumab), was approved in February 2007 for Crohn's. Atlantic Information Services, Inc., Humira FDA-Approved for Juvenile Idiopathic Arthritis - Feb 24, 2008 Humira (adalimumab) has been approved by the United States Food and Drug Administration (FDA) as a treatment to reduce the signs and symptoms of moderately About - News & Issues, MG Strategies: Has added Abbott Laboratories to their watch list. - Feb 22, 2008 Friday February 22, 2008, Abbott announced it has received US Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to Trading Markets (press release), Abbott Gets FDA Approval To Market Humira To Treat Juvenile ... - Feb 22, 2008 ...(RTTNews) - Abbott Laboratories (ABT | news | PowerRating | PR Charts ) on Friday said it has received FDA approval to market Humira or adalimumab to treat Trading Markets (press release), Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate ... - Jan 18, 2008 18 /PRNewswire-FirstCall/ -- Abbott announced today it has received US Food and Drug Administration (FDA) approval to market HUMIRA(R) (adalimumab) as a CNNMoney.com Adalimumab (Humira) Okayed for Psoriasis - Jan 21, 2008 21 -- The FDA has approved adalimumab (Humira), a tumor necrosis factor blocker, for moderate to severe chronic plaque psoriasis, Abbott announced here. MedPage Today, Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate ... - Jan 18, 2008 By Abbott Abbott (NYSE: ABT) announced today it has received US Food and Drug Administration (FDA) approval to market HUMIRA(R) (adalimumab) as a treatment Biloxi Sun Herald, Abbott and Eisai Announce Changes in the Sales Scheme in Japan for ... - Jan 28, 2008 With these changes, Eisai and Abbott have finalized the basic agreement concerning co-development and marketing for adalimumab in Japan. PharmaLive.com (press release), Market Report -- In Play (ABT) - Jan 18, 2008 Abbott's HUMIRA (adalimumab) receives FDA approval for moderate to severe chronic plaque psoriasis Co announced it has received US Food and Drug MSN Money Abbott Receives FDA Approval For HUMIRA As Treatment For Adult ... - Jan 18, 2008 Food and Drug Administration approval to market HUMIRA or adalimumab as a treatment for adult patients with moderate to severe chronic plaque psoriasis. Trading Markets (press release), Denosumbab May Hold Key For an Amgen Recovery? - Feb 2, 2008 ...as no surprise to physicians, and he said Enbrel's safety profile should allow it to overcome competition from Humira (adalimumab, Abbott) in psoriasis. BioWorld Online, Elan and Biogen Idec: Tysabri uptake in Crohn's disease will be ... - Jan 15, 2008 Moreover, it is estimated that most patients with CD who terminate therapy with Remicade are switched to treatment with Abbott's Humira (adalimumab), Trading Markets (press release), TNF Blockers Affect B-Cell Activity in Rheumatoid Arthritis - Jan 29, 2008 ...and Humira (adalimumab) -- may also eliminate abnormal B-cell activity. Researchers studied 45 patients with rheumatoid arthritis and 22 healthy adults. About - News & Issues, Abbott swings back into the black - Jan 24, 2008 Notably, the group’s anti-inflammatory Humira (adalimumab) generated revenues of $954 million, a 54% increase on the year-earlier period, while sales of the Pharma Times (subscription), New HIV Therapy, Other Products Get FDA Approval - Jan 22, 2008 In another indication expansion, Abbott’s Humira (adalimumab) was approved by the FDA for the treatment of moderate to severe chronic plaque psoriasis. FDA news (subscription), FDA approves Tysabri as treatment for Crohn's disease - Jan 15, 2008 ...such as Abbott’s Humira (adalimumab) and Johnson & Johnson/Schering-Plough’s Remicade (infliximab), “there remains a significant unmet need for Crohn's Pharma Times (subscription), FDA Approves Natalizumab (Tysabri) for Crohn's Disease - Jan 14, 2008 Conventional therapies for Crohn's disease include corticosteroids and tumor necrosis factor inhibitors such as infliximab (Remicade) and adalimumab MedPage Today, Harvard Medical School: The Top 5 Health Stories of 2007 - Jan 8, 2008 Now two others — infliximab (Remicade) and adalimumab (Humira) — are on the market, and a third — certolizumab — is waiting in the wings. HealthNewsDigest.com, Arthritis Patients Denied Access to New Treatment - 19 Dec 2007 As well, Canada's Common Drug Review recently reviewed Humira (adalimumab), one of three approved biologics for AS, and recommended that provincial Market Wire (press release) Drug Combos Effective Against Rheumatoid Arthritis - Nov 26, 2007 They also found that methotrexate was as effective as the biologics adalimumab and etanercept in early rheumatoid arthritis. Adalimumab and etanercept had Washington Post, Combining Medications Often Best Strategy To Battle Rheumatoid ... - Nov 20, 2007 The report also found that methotrexate works as effectively as the biologic dmards adalimumab and etanercept for patients who have early rheumatoid Science Daily (press release) Mother wins funding for 'wonder' drug - Nov 27, 2007 The other drugs are adalimumab and infliximab and all fall under the same umbrella of biologic immunosuppressants. She said: "The trial was meant to be just News Shopper, tgaac94 exonerated in US trial death - Nov 19, 2007 The other medications the subject was taking - adalimumab, methotrexate and prednisone - are known to be immunosuppressive and a risk factor for histoplasma PR-USA.net (press release), FDA Removes Hold on TgAAC94 Trial - Nov 26, 2007 The subject was on adalimumab, methotrexate and prednisone, which are known to be immunosuppressive and a risk factor for histoplasma infection, FDA news (subscription), Paper of the Day - No one RA treatment better than the other - Nov 23, 2007 ...the conventional DMARDs studied - methotrexate, leflunomide or sulfasalazine – or among the biologic therapies – adalimumab, etanercept or infliximab. Pulse, EU Panel Backs Glaxo's Tykerb, And 2 Teva Generics -3- - Dec 14, 2007 Humira (adalimumab), from Abbott Laboratories, to include reduction in the rate of progression of joint damage and improvement of physical function in the EasyBourse.com, Targeted Genetics Reports on Recombinant DNA Advisory Committee ... - Dec 3, 2007 ...patient's susceptibility to the infection was the patient's longstanding systemic treatment for rheumatoid arthritis with a TNF antagonist, adalimumab. CNNMoney.com Pharmaceutical Market Research Report Says Monoclonal Therapeutics ... - Dec 12, 2007 Adalimumab (branded Humira), made by Abbott, a recombinant human monoclonal antibody specific for human tumor necrosis factor that was created through phage Business Wire (press release), Gene therapy trial to restart - Nov 27, 2007 And levels of the relevant anti-inflammatory proteins were well within expected limits, given that Mohr was also taking Humira (adalimumab), Nature.com (subscription), Little difference among rheumatoid arthritis drugs - Nov 20, 2007 They also looked at biological dmards such as abatacept, made by Bristol-Myers Squibb Co. under the brand name Orencia; adalimumab, sold by Abbott Tehran Times, Potential Drugs for Improving Chronic Fatigue Syndrome - Dec 10, 2007 3) Adalimumab, a fully human antibody to the tumor necrosis factor, is used in cutaneous sarcoidosis. 4) Thalidomide has immunomodulatory and Journal of Neuropsychiatry (subscription) Six Therapeutic Drug Categories That Could See Important New Drugs ... - Dec 6, 2007 ..."That will allow the product to more adequately compete" with Humira (adalimumab), marketed by Abbott, and Enbrel (etanercept), marketed by Amgen and Wyeth Atlantic Information Services, Inc., Rheumatoid arthritis drugs: all the same? - Dec 4, 2007 ...such as leflunomide, methotrexate and sulfasalazine and biological modifying drugs, such as adalimumab, etanercept and infliximab. IIT Tech News, Biologics offer new option for treating psoriasis in children - Nov 30, 2007 Adalimumab is awaiting approval from the Food and Drug Administration. Etanercept is a recombinant tumor necrosis factor (TNF) alpha receptor fusion protein AAP News (subscription) Risk of Diabetes in Patients With Rheumatoid Arthritis Taking ... - Nov 27, 2007 ...rheumatoid arthritis treated with anti–TNF- medications (etanercept, infliximab, or adalimumab) was 1.05 (95% confidence interval, 0.50-2.21; P = .89). Journal of American Medical Association (subscription), Arthritis Gene Therapy Trial Resumes After Patient Death Investigated - Nov 27, 2007 Apart from the experimental drug, the patient was also taking adalimumab, methotrexate and prednisone, which are known to suppress the immune system, Medical News Today, Targeted Genetics restarts trial after death - Nov 26, 2007 She was also taking Abbott's TNF blocker Humira (adalimumab), methotrexate and prednisone. "[These] are known to be immunosuppressive and a risk factor for DrugResearcher.com, Roche files Actemra with FDA for rheumatoid arthritis - Nov 22, 2007 ...for RA – Abbott Laboratories’ Humira (adalimumab), Johnson & Johnson/Schering-Plough’s Remicade (infliximab) and Wyeth/Amgen’s Enbrel (etanercept). Pharma Times (subscription), Anti-TNF efficacy tied to rheumatoid arthritis patient selection - Nov 21, 2007 Kievit of Radboud University Nijmegen and colleagues examined 11 RCTs involving RA patients who were treated with etanercept, infliximab or adalimumab. Therapeutics Daily (subscription) (press release), Abbott's HUMIRA Receives Positive Opinion from EMEA for Treatment ... - Nov 20, 2007 ...granted Abbott a positive opinion recommending approval of HUMIRA (adalimumab) for the treatment of moderate to severe plaque psoriasis. Nutrition horizon (press release), Brand Names/Synonyms: Adalimumab is also known by the following brand names and/or synonymsIg gamma-1 chain C region; Humira (Abbott Laboratories) Drug Category: Adalimumab is categorized under the following by the FDA: Immunomodulatory Agents; Antirheumatic Agents; unclassified therapeutic agents (92:00.00) Dosage Forms: Solution Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Humanized anti-TNF antibody (D2E7) : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |